🚨 Trade Update: AEHR — Both Price Targets Hit ✅✅
We recommended Aehr Test Systems, Inc. (NASDAQ: AEHR) on April 7, 2026, at a buy level of $52.70, with price targets of $66.00 (PT1) and $80.00 (PT2) and a stop-loss at $44.50 on a closing basis.
Both targets have been achieved — PT2 was reached on April 16, 2026, delivering gains of approximately 25% and 52% from the entry level in just over a week. The stock continued to run well beyond PT2 before pulling back sharply in recent weeks, and is now trading around $68.02 — still up roughly 29% from our original entry level.
Bottom line: Both targets hit in just over a week for as much as ~52% upside — AEHR has cooled off from its highs since but remains up ~29% from entry. And now, on to today’s featured setup…
Biogen Inc. (NASDAQ: BIIB) just broke out and looks headed even higher.
As we’ll get to just ahead, the combination of a major regulatory breakthrough, a key clinical readout that could open up a huge second growth market, and a fresh technical breakout makes BIIB one of the more interesting setups on the board. Here’s what’s going on…
The Themes Behind the Move
Biogen is a global biotechnology company that discovers, develops, and manufactures therapies for some of the hardest-to-treat conditions in medicine — a lineup that spans multiple sclerosis (MS), spinal muscular atrophy, Alzheimer’s disease, and a growing set of rare and immunology conditions. Its best-known franchises include the MS drugs TECFIDERA and TYSABRI, the spinal muscular atrophy treatment SPINRAZA, and — most importantly for today’s story — the Alzheimer’s drug LEQEMBI, developed with partner Eisai.
In plain English, Biogen spent years known primarily as an aging MS company whose biggest products were slowly losing ground. The story now is a turnaround: its high-margin newer drugs — led by the Alzheimer’s franchise — are reaching commercial maturity just as the company diversifies into immunology and rare disease through fresh deals and pipeline data. The market is starting to price in that transition, and the chart is confirming it.
BIIB’s latest move reflects a powerful confluence of developments — clinical, regulatory, and commercial — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.
| Theme / Catalyst | What Happened | Why Traders Care |
|---|---|---|
| Leqembi at-home autoinjector approved | The FDA approved LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector version of Biogen and Eisai’s Alzheimer’s drug — two roughly 15-second injections that can be given at home. Data presented at AAIC 2026 showed the formulation delivers identical drug exposure, safety, and efficacy to the standard bi-weekly IV infusion. | The biggest bottleneck to Leqembi’s rollout has been the shortage of infusion-clinic capacity. Shifting patients to a convenient at-home weekly shot radically lifts how fast the drug can scale — and survey data puts patient satisfaction with the new format between 75% and 97%. This is the single most important adoption catalyst for Biogen’s fastest-growing franchise. |
| Potential best-in-class Alzheimer’s asset in the clinic | Biogen is presenting Phase 2 data from its CELIA study of diranersen (BIIB080) at the Alzheimer’s Association International Conference in London. Unlike today’s approved drugs — which clear amyloid plaques outside brain cells — diranersen is designed to lower the production of tau, the protein tangles inside brain cells tied more directly to cognitive decline. | A clean efficacy signal here would give Biogen a potential best-in-class, multi-billion-dollar second Alzheimer’s asset with a different mechanism than anything on the market. Management commentary has already generated significant optimism, making this readout a high-impact swing factor for the stock. |
| Pipeline momentum and dealmaking | Beyond Alzheimer’s, Biogen has been building out newer growth engines: positive readouts for dapirolizumab pegol in lupus, a high-dose Spinraza approval for spinal muscular atrophy, and acquisitions adding immunology and ophthalmology assets (Syfovre/Empaveli). | This diversifies Biogen well beyond its declining MS franchise into Alzheimer’s, immunology, and rare disease — the multi-year growth drivers that support the turnaround thesis and give the company several independent shots on goal. |
| Sector tailwinds | The broader biotech landscape is in an innovation-driven upswing, helped by regulators’ growing willingness to accept biomarker-based accelerated approvals and a structural shift toward convenient at-home biologics. Large pharma, meanwhile, is facing steep patent-cliff revenue losses and is hunting for commercialized neurology pipelines to buy. | Biogen’s tight focus on neurodegenerative diseases (Alzheimer’s, ALS, Friedreich’s Ataxia) positions it as a prime beneficiary of that demand — whether through direct acquisition interest or high-value co-development partnerships. |
| Fundamentals and balance sheet | Q1 revenue came in at $2.48B (+2%), with growth products up +12% to $851M, and Biogen beat on non-GAAP EPS. The company carries a cash cushion of over $1.9B and trades at a forward P/E of roughly 12x — historically cheap for an established biotech innovator. | A legacy MS decline is being offset by ramping new launches, cost savings from a reorganization, and ample dry powder for further dealmaking. Cheap valuation plus a strengthening pipeline is exactly the combination that draws value-conscious biotech investors. |
| Analyst coverage | Across the 31 analysts issuing twelve-month price targets on BIIB, the average sits at $220.04, with a high of $300.00 and a low of $157.00. Recent moves skew bullish: Truist upgraded to Buy at $235 post-approval, RBC raised to Buy at $242, and Jefferies has a Buy at $255. | The high-end $300 target and a cluster of fresh raises in the $235–$255 zone point to a coverage universe that may still be catching up to the subcutaneous approval and pipeline news. Truist’s upgrade in particular looks like an opening move ahead of the July 29 earnings report. |
| Upcoming triggers | The near-term calendar is stacked: Q2 2026 earnings on July 29 (key for a Leqembi update, deal impacts, and guidance), ongoing AAIC 2026 data presentations including the diranersen and lupus programs, plus additional regulatory milestones (Spinraza expansions) and potential further dealmaking. | A staggered set of catalysts — earnings, pipeline readouts, and regulatory updates — each capable of independently moving the stock over the coming weeks and months, with the July 29 print as the first big test. |
If needed, swipe or scroll sideways to view the full table.
Put it all together, and BIIB is looking less like a fading MS company leaning on legacy products and more like a diversifying neurology franchise with a major new adoption catalyst (the at-home Leqembi autoinjector), a potential best-in-class Alzheimer’s asset in the clinic, a cheap valuation, a fortified balance sheet, and a stacked catalyst calendar into earnings.
The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.
Bullish Technical Signals
#1 Uptrend Channel: BIIB continues to grind higher inside a well-defined ascending channel (purple). Price has just turned up off the lower rail and is heading back toward the upper boundary. That’s the setup to watch: a push through the upper rail marks a channel breakout, which typically releases price into a faster leg higher. Until then, the lower rail defines the trend — as long as it holds on a closing basis, the path of least resistance stays up.
BIIB – Daily Chart
#2 Price above MAs: BIIB trades above both its 50-day (197.78) and 200-day (179.46) SMAs, and the 50-day sits above the 200-day — a golden-cross alignment confirming the intermediate and long-term trends point the same way. Price holding above stacked, rising averages signals that overhead supply has been absorbed. On any pullback, those two averages layer up as dynamic support, giving buyers defined levels to defend.
#3 Bullish ADX: Direction and strength are lining up together. +DI (27.44) sits above –DI (20.98), so buyers hold the directional edge. At the same time, ADX (22.10) has turned up through the 20 line — the threshold where a market shifts from choppy to genuinely trending. A rising ADX with +DI on top says the move isn’t just higher, it’s gaining conviction: the configuration you want to see when a trend is starting to accelerate rather than stall out.
#4 Bullish Stoch: %K has crossed above %D as the oscillator climbs out of oversold. The crossover alone is low-signal; emerging from an oversold base is what gives it weight. It marks the point where selling pressure has exhausted and fresh buying is stepping in — momentum turning up from a washed-out low rather than an extended one, which leaves room to run before it reaches overbought.
#5 Above Support Area: On the weekly, BIIB has moved back above a former resistance level that now acts as support (pink dotted, ~194). Old resistance flipping to support is one of the more reliable structural tells: traders who once sold there tend to defend it on the way back up. Price also holds above the 50-week SMA (174.99), keeping the weekly trend firmly bullish. The one hurdle left overhead is the 200-week SMA (~209.47), which this week’s strong bullish candle (+4.96%) is pressing directly into — a decisive weekly close above it clears the last major moving-average obstacle and dovetails cleanly with the $212.50 buy trigger.
BIIB – Weekly Chart
#6 Bullish Aroon: Aroon Up sits at 85.71 while Aroon Down has collapsed to 0.00 — about as clean a bullish reading as the indicator produces. Aroon Up above 70 confirms price is regularly printing fresh highs across the lookback window; Aroon Down at zero means sellers have been entirely absent from setting new lows. That wide, sustained separation points to an established, uncontested uptrend rather than an early or fragile one.
#7 Bullish MACD: The weekly MACD line (9.17) is above its signal (8.27) with the histogram flipped positive — a fresh bullish crossover, and one occurring with both lines above the zero line, which keeps momentum on the bulls’ side rather than merely attempting a turn. The timing is what gives it weight: the cross is firing as price breaks higher, so the oscillator is corroborating the price action instead of diverging from it. Short-term momentum is re-accelerating in step with the breakout.
Risks to Consider
Even strong setups can fail, especially in a large-cap biotech like Biogen. A few things could knock the stock off course:
- A breakdown from the uptrend channel on heavy volume would invalidate the breakout thesis and flip the near-term trend lower
- Negative company-specific news, broader market weakness, or any regulatory shift in the sector could trigger a sharp sell-off
- Legacy MS franchise decline — continued erosion in Tecfidera and Tysabri revenue remains a structural headwind that new launches must outrun
- Pipeline and execution risk — clinical setbacks are always possible (Biogen has discontinued programs before), and integrating recent acquisitions like Apellis carries its own risk
- Near-term earnings and valuation pressure — IPR&D charges and deal-related milestones can weigh on reported EPS, and the stock’s forward multiple leaves less room for error if a quarter disappoints
- Competition — the Alzheimer’s space is crowded, with Eli Lilly’s Kisunla (donanemab) a direct rival to Leqembi in the commercial land-grab
- Access and reimbursement hurdles — high-cost therapies face payer pushback, and strict diagnostic requirements (PET scans, CSF draws) can slow new-patient onboarding
- Catalyst risk cuts both ways — a disappointing diranersen readout at AAIC or a soft Q2 print on July 29 could unwind the recent momentum quickly
The Bottom Line
BIIB is turning up off the lower rail of a well-defined uptrend channel on the daily chart while reclaiming a former resistance-turned-support level and pressing into its 200-week moving average on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.
The fundamental story underneath the chart is just as strong: a major new at-home approval for its flagship Alzheimer’s drug, a potential best-in-class Alzheimer’s asset now in the clinic, and a cheap ~12x forward valuation backed by a $1.9B+ cash cushion.
Combine that with multiple catalysts staggered through the coming weeks — Q2 earnings on July 29, ongoing AAIC pipeline readouts, and further regulatory milestones and potential dealmaking — and BIIB looks like one of the more compelling risk-reward setups on the board right now.
If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 12%–21% potential upside, and the stop-loss we’re using to manage the downside.
Recommended Trade Setup
| Item | Detail |
|---|---|
| Buy Level | Above approximately $212.50 |
| Price Target 1 | $238.00 — Potential upside: 12% |
| Price Target 2 | $258.00 — Potential upside: 21% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $198.00 on a closing basis |
| Trade Invalidation | Void if price hits stop-loss before entry triggers |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $14.50 per share, the target rewards are about $25.50 and $45.50 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If BIIB drops to or below the $198.00 stop-loss before the $212.50 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.
Happy Trading!
Tara and Greg
🥈 Almost Made the Cut
Today’s featured trade, Biogen Inc. (NASDAQ: BIIB), was our top pick of several breakout candidates we evaluated. The following two stocks were strong candidates that made it to the final round — they came up just short of the top spot, but remain on our watchlist and could be featured soon:
Cheniere Energy, Inc. (NYSE: LNG) — One of the highest-quality infrastructure growth stories in the market, with continued execution on Corpus Christi Stage 3, expanding LNG export capacity, upgraded cash-flow guidance, and strong long-term contracted revenue. The stock has reclaimed both its 50-day moving average and a major volume-support zone, and options activity favors upside into August earnings — though the recent advance has already priced in some of the near-term optimism, leaving slightly less asymmetry than our top pick.
UiPath Inc. (NYSE: PATH) — One of the more compelling enterprise-AI turnaround stories, having just posted its first GAAP operating profit as customers move from AI experimentation into full production deployments. New products, aggressive buybacks, expanding enterprise ARR, and elevated short interest set up the potential for a meaningful re-rating — though the stock is still working to decisively reclaim its 200-day moving average, making it a slightly earlier-stage technical recovery than today’s featured pick.
